(EMAILWIRE.COM, August 25, 2009 ) DALLAS (August 25, 2009) BeaconEquity.com announces an investment report featuring drug maker SPPI' style=''>Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI).

The investment report on Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) should be of particular interest to other pharmaceutical companies: Abbott Laboratories (Nasdaq: ABT), Bristol Myers Squibb Co. (NYSE: BMY) and Eli Lilly & Co. (NYSE: LLY).

It is available at: http://www.beaconequity.com/i/SPPI

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

Spectrum Pharmaceuticals Inc. (SPPI) is a developer, manufacturer and marketer of therapies through proprietary anti-cancer technologies to fight cancer. The Company is in commercial stage with its drug therapy Zevalin, a radioimmunotherapy for the treatment of non-Hodgkin's Lymphoma. Other drug therapies under development include Fusilev to treat osteosarcoma; Apaziquone to treat non-muscle invasive bladder cancer; Ozarelix, in phase II trials to treat benign prostatic hypertrophy; Ortataxel, a third-generation taxane. The Company also carries exclusive rights to Renazorb and Renanal, worldwide.

In the report, the analyst notes:

“According to the Cancer Market Outlook report published by Business Insights, the market for cancer therapeutic drugs is expected to reach $40.9 billion by 2012. The Company's partner, Cell Therapeutics Inc., is a leading maker of drug therapies for the treatment of cancer. …

“If approved by the U.S. Food and Drug Administration (FDA), the market for SPPI’s drug candidate Zevalin could reach more than $1 billion at its market saturation. Brostallicin is the Company's phase II drug candidate for the treatment of sarcoma, with prospects of reaching commercialization at approximately 50% following successful completion of phase II.”

To read the entire report visit: http://www.beaconequity.com/i/SPPI

BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.


Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com

Contact Information:
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us


This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.